Brokerages Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Price Target at $8.14

Quince Therapeutics, Inc. (NASDAQ:QNCX) has been assigned a consensus rating of “Buy” from the eleven ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $8.1429.

QNCX has been the topic of a number of research analyst reports. Zacks Research upgraded Quince Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Wall Street Zen lowered Quince Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Citigroup began coverage on Quince Therapeutics in a research report on Tuesday, August 5th. They set an “outperform” rating on the stock. D. Boral Capital reiterated a “buy” rating and set a $4.00 price objective on shares of Quince Therapeutics in a research report on Friday, August 15th. Finally, Citizens Jmp began coverage on Quince Therapeutics in a research report on Tuesday, August 5th. They set a “strong-buy” rating and a $9.00 price objective on the stock.

Hedge Funds Weigh In On Quince Therapeutics

Institutional investors have recently modified their holdings of the company. Two Sigma Investments LP bought a new position in shares of Quince Therapeutics during the 4th quarter valued at about $57,000. Northern Trust Corp grew its position in Quince Therapeutics by 48.5% during the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock worth $94,000 after acquiring an additional 16,501 shares during the last quarter. Ieq Capital LLC bought a new position in Quince Therapeutics during the 1st quarter worth approximately $1,073,000. Virtu Financial LLC grew its position in Quince Therapeutics by 48.4% during the 1st quarter. Virtu Financial LLC now owns 43,332 shares of the company’s stock worth $58,000 after acquiring an additional 14,128 shares during the last quarter. Finally, Shay Capital LLC grew its position in Quince Therapeutics by 60.8% during the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock worth $518,000 after acquiring an additional 104,616 shares during the last quarter. 30.75% of the stock is currently owned by institutional investors.

Quince Therapeutics Price Performance

Shares of NASDAQ QNCX opened at $1.58 on Tuesday. The firm has a market capitalization of $84.86 million, a P/E ratio of -1.45 and a beta of 0.99. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 1.45. The stock’s 50-day simple moving average is $1.68 and its two-hundred day simple moving average is $1.38. Quince Therapeutics has a twelve month low of $0.69 and a twelve month high of $2.45.

Quince Therapeutics (NASDAQ:QNCX) last announced its earnings results on Monday, August 11th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). As a group, equities analysts anticipate that Quince Therapeutics will post -1.21 EPS for the current fiscal year.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.